Dexfenfluramine, fenfluramine, and phentermine for the treatment of morbid obesity.
نویسنده
چکیده
iv
منابع مشابه
Anorectic therapy and valvular heart disease: a reappraisal.
Pharmacotherapy has become an increasing popular strategy for treatment of obesity in part to avoid its associated morbid cardiac and cerebrovascular complications. The appetite suppressing agents phentermine and fenfluramine were introduced in 1959 and 1979, respectively. Fenfluramine is a sympathomimetic amine that evokes an anorectic effect by promoting the release and inhibiting neuronal re...
متن کاملNational trends in antiobesity medication use.
BACKGROUND The use of medications to treat obesity remains controversial. Our goal was to assess national trends in antiobesity medication use with a focus on patterns surrounding the 1997 removal of antiobesity drugs from the market. METHODS Using a serial cross-sectional study design, we analyzed a nationally representative sample of US office-based physician visits from 1991 to 2002. Data ...
متن کاملAnesthetic considerations for the new antiobesity medications.
Combination drug therapy can effectively treat the problem of obesity. The most commonly used combination is a mix of fenfluramine and phentermine. Fenfluramine inhibits the reuptake of serotonin and acts on the hypothalmic appetite control center, while phentermine acts as an appetite suppressant. These drugs along with diet and exercise effectively help people to lose weight with few side eff...
متن کاملPharmacologic Treatment of Obesity
This review offers an overview of physiological agents, current therapeutics, as well as medications, which have been extensively used and those agents not currently available or non-classically considered anti-obesity drugs. As obesity - particularly that of central distribution - represents an important triggering factor for insulin resistance, its pharmacological treatment is relevant in the...
متن کاملAminorex to Fen/Phen An Epidemic Foretold
Over the years, a variety of diets and drugs for the treatment of obesity have come and gone. More recently, newspapers, radio, and television have featured the rise and fall of the latest appetite-suppressants, dexfenfluramine and the combination of fenfluramine and phentermine (fen/phen). The rise occurred after approval of dexfenfluramine by the Food and Drug Administration (FDA); the fall w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of the American Academy of Nurse Practitioners
دوره 9 8 شماره
صفحات -
تاریخ انتشار 1997